Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257392 | 0.79 | PTPN2 (0.37) | PTPN2PTPN1CDC25BIDO1ALOX15 | |
| SCHEMBL14747552 | 0.76 | IDO1 (0.63) | PTPN2PTPN1CDC25BIDO1ALOX15 | |
| SCHEMBL12986595 | 0.76 | IDO1 (0.68) | CDC25BIDO1ALOX15 | |
| SCHEMBL10295726 | 0.70 | ALOX15 (0.35) | PTPN2PTPN1CDC25BALOX15 | |
| SCHEMBL1187679 | 0.70 | IDO1 (0.57) | PTPN2PTPN1CDC25BIDO1 | |
| SCHEMBL21675638 | 0.69 | ALOX15 (0.34) | PTPN2PTPN1CDC25BALOX15 | |
| SCHEMBL10446161 | 0.69 | ALOX15 (0.38) | PTPN2PTPN1CDC25BALOX15 | |
| SCHEMBL2026471 | 0.69 | ALOX15 (0.34) | PTPN2PTPN1CDC25BALOX15 | |
| SCHEMBL8125090 | 0.69 | PTPN2 (0.46) | PTPN2PTPN1CDC25BIDO1ALOX15 | |
| SCHEMBL1187716 | 0.68 | PTPN1 (0.68) | PTPN2PTPN1CDC25BIDO1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-02-17 | — | — | US | disclosed |
| US-11179482-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2021-11-23 | — | — | US | disclosed |
| US-20200237932-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-07-30 | — | — | US | disclosed |
| US-10660974-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-05-26 | — | — | US | disclosed |
| US-20190290787-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660974-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | DAXX, DCAF15, DCAF1 | PTPN2 3363/4885PTPN1 3217/4885CDC25B 4249/4885 |
| US-20200237932-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, CDY1; CDY1B | PTPN2 2791/4885PTPN1 2721/4885CDC25B 3974/4885 |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | PTPN2 330/4885PTPN1 293/4885CDC25B 265/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PTPN2 1553/4885PTPN1 1552/4885CDC25B 853/4885 |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | PTPN2 938/4885PTPN1 961/4885CDC25B 117/4885 |
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, CDY1; CDY1B | PTPN2 2791/4885PTPN1 2721/4885CDC25B 3974/4885 |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | PTPN2 970/4885PTPN1 1764/4885CDC25B 46/4885 |
| US-11179482-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | DAXX, DCAF15, CDY1; CDY1B | PTPN2 2791/4885PTPN1 2721/4885CDC25B 3974/4885 |
| US-20190290787-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, DCAF1 | PTPN2 3363/4885PTPN1 3217/4885CDC25B 4249/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | PTPN2 1037/4885PTPN1 1473/4885CDC25B 60/4885 |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | PTPN2 1273/4885PTPN1 1813/4885CDC25B 53/4885 |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | PTPN2 2946/4885PTPN1 3034/4885CDC25B 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.